SAN DIEGO, March 29 (Bernama-GLOBE NEWSWIRE) -- Invivoscribe®
Technologies Inc., a global company with decades of experience
providing internationally standardized clonality and biomarker testing
solutions for the fields of oncology, personalized molecular diagnostics®, and personalized molecular medicine®, reports that its next-generation sequencing (NGS) LymphoTrack® Assay kits are being used by its LabPMM®
clinical laboratories, pharmaceutical partners, and cancer centers to
identify and monitor chimeric antigen receptor T-cells (CAR-T) and
engineered T-cell receptors in peripheral blood of subjects in support
of immuno-therapeutic drug development and treatment regimen development
for both hematologic and solid tumors.
http://mrem.bernama.com/viewsm.php?idm=28784
No comments:
Post a Comment